Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus ...

If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares ...

Johnson & Johnson's (NYSE: JNJ) stock price is up more than 7% since the first trading day of November. What's going on with this healthcare giant? Well, J&J posted strong third-quarter results in mid ...

Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price⁠ tar⁠g⁠et o⁠n Johnson & Johnson (NYSE:JNJ) to $197 from $176 on December 2 ...

The average one-year price target for Johnson & Johnson (XTRA:JNJ) has been revised to 175,39 € / share. This is an increase of 11.93% from the prior estimate of 156,70 € dated September 29, 2025. The ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for ...

The U.S. Food and Drug Administration on Monday awarded a national priority voucher to Johnson & Johnson’s (NYSE: JNJ) Tecvayli (teclistamab) in combination with daratumumab for relapsed/refractory ...

J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment. 10 stocks we like better than ...